News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Yibai Pharma To Acquire Horus C&K Pharma For $128 Million


7/16/2014 8:52:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Guizhou Yibai Pharma will pay $128 million to acquire Tianjin Horus C&K Pharmaceutical. Horus reported revenues of $32 million and profits of $6 million in 2013, pricing the purchase and 4X sales and 21X profit. However, the company’s business seems to be improving this year. In the first five months of 2014, Horus’ sales are up 30% and profits climbed 65%. Horus makes five products: two generic chemicall drugs and three TCM products. One TCM is an exclusive product for Horus.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES